Organigram Global shares rise 10.14% premarket after announcing $230M acquisition of Sanity Group with BAT equity investment.

Organigram Global surged 10.14% in premarket trading following the announcement of a definitive agreement to acquire the remaining 91% stake in The Sanity Group GmbH for €230 million. The transaction, expected to be financially accretive, is projected to enhance revenue and profitability, with funding secured via a combination of cash, a private placement investment, and a credit facility. The deal, subject to regulatory approvals and shareholder approval on March 30, 2026, is anticipated to close in Q2 2026. Additionally, British American Tobacco’s decision to receive Organigram shares as part of the consideration for its interest in Sanity underscores confidence in the company’s strategic direction. The acquisition aligns with Organigram’s goal to establish itself as a global cannabis industry leader, reinforcing investor optimism.